Understanding the role of the CYP4/20-HETE/GPR75 axis in the progression of MASLD and the effective management of portal hypertension in CLD and cirrhosis may provide new therapeutic avenues to treat these progressive liver diseases (Figure 1). This evidence concerns the gene GPR75 and metabolic dysfunction-associated steatotic liver disease.